Affinity Asset Advisors LLC Acquires 20,000 Shares of Mineralys Therapeutics, Inc. $MLYS

Affinity Asset Advisors LLC grew its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 2.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 750,000 shares of the company’s stock after purchasing an additional 20,000 shares during the period. Mineralys Therapeutics comprises approximately 1.0% of Affinity Asset Advisors LLC’s holdings, making the stock its 29th largest holding. Affinity Asset Advisors LLC owned approximately 0.91% of Mineralys Therapeutics worth $20,318,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Mineralys Therapeutics by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after acquiring an additional 702 shares in the last quarter. Navalign LLC purchased a new stake in shares of Mineralys Therapeutics in the 4th quarter worth approximately $33,000. Velan Capital Investment Management LP raised its holdings in Mineralys Therapeutics by 0.6% in the third quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company’s stock worth $6,659,000 after purchasing an additional 1,000 shares in the last quarter. Royal Bank of Canada raised its holdings in Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock worth $56,000 after purchasing an additional 1,107 shares in the last quarter. Finally, KBC Group NV purchased a new stake in shares of Mineralys Therapeutics during the first quarter valued at about $33,000. 84.46% of the stock is currently owned by institutional investors.

Mineralys Therapeutics Stock Down 1.1%

Shares of NASDAQ MLYS opened at $26.71 on Friday. The firm has a 50-day simple moving average of $27.05 and a 200-day simple moving average of $28.24. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -13.03 and a beta of 0.66. Mineralys Therapeutics, Inc. has a 52 week low of $12.59 and a 52 week high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04. As a group, equities research analysts expect that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current year.

Analysts Set New Price Targets

MLYS has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. Wall Street Zen lowered Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. TD Cowen started coverage on shares of Mineralys Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating for the company. Finally, HC Wainwright reissued a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Mineralys Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $49.33.

Insider Buying and Selling

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $30.30, for a total transaction of $65,781.30. Following the transaction, the insider directly owned 57,733 shares of the company’s stock, valued at $1,749,309.90. The trade was a 3.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 104,124 shares of Mineralys Therapeutics stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $25.90, for a total transaction of $2,696,811.60. Following the sale, the insider directly owned 38,400 shares in the company, valued at approximately $994,560. The trade was a 73.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 230,280 shares of company stock valued at $6,018,442 over the last 90 days. Insiders own 18.94% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.